FIRALIS is a biotechnology company located at the triple border of Europe, creating novel values via biomarker discovery, development, and regulatory qualification of biomarker-based diagnostic products. With a comprehensive expertise in the field, Firalis develops diagnostic kits and provides an extensive range of biomarker services to improve therapeutic decisions as well as disease outcomes and patient comfort, finally to reduce healthcare costs at remarkable extents.
Activities of Firalis mainly but non-exclusively involve biomarkers of inflammatory disorders such as atherosclerosis, rheumatoid arthritis, rare/orphan diseases such as systemic or autoimmune vasculitis. For numerous of its R&D projects, Firalis has been awarded countless of times with respectful research and entrepreneurship awards as well as significant research grants which allowed us to conduct some of the largest clinical biomarker studies ever in Europe.
Overall, Firalis offers a unique challenge & experience.